Relmada Therapeutics

New treatments like COMP360, Zuranolone, LY03005, REL-1017, Seltorexant, and ABV-1504 are expected to significantly transform the major depressive disorder (MDD) market. MDD affects 44 million diagnosed cases in the 7MM, with moderate cases being the most prevalent. Treatment approaches include pharmacological interventions, psychotherapy, and lifestyle changes. The market size for MDD is projected to grow from USD 7.1 billion in 2023, driven by disease awareness and new product launches.

Relmada Therapeutics focuses on developing REL-1017 for MDD, with an interim analysis for the Reliance 2 Phase 3 study expected by year-end 2024. The company reported a decrease in cash and investments to $54.1 million and a net loss of $21.7 million for Q3 2024, with increased R&D spending. Ongoing studies include a Phase 1 safety study for a psilocybin-based candidate and plans for a Phase 2a study in 2025.

Relmada Therapeutics (Nasdaq: RLMD) reported a net loss of $21.7 million for Q3, with $54.1 million in cash but projecting insufficient liquidity to sustain operations for a year. The company aims to achieve key milestones by year-end, including interim analysis for the Reliance II study and initiating the REL-P11 Phase I study.

Relmada Therapeutics provides update on REL-1017 Phase 3 program, including Reliance II interim analysis expected by YE 2024, and plans to initiate Phase 1 study for REL-P11 for metabolic disease by YE 2024. The company reports a cash position of $54.1 million, supporting operations through key milestones into 2025.